- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00600015
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Fort Myers, Florida, United States, 33901
- Florida Cancer Specialists
-
-
Georgia
-
Gainesville, Georgia, United States, 30501
- Northeast Georgia Medical Center
-
Marietta, Georgia, United States, 30060
- Wellstar Cancer Research
-
-
Kansas
-
Overland Park, Kansas, United States, 66210
- Kansas City Cancer Centers
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Center For Cancer and Blood Disorders
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Grand Rapids Clinical Oncology Program
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Methodist Cancer Center
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Cancer Care of Western North Carolina
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- Oncology Hematology Care
-
Columbus, Ohio, United States, 43219
- Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center
-
-
South Carolina
-
Columbia, South Carolina, United States, 29210
- South Carolina Oncology Associates, PA
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Chattanooga Oncology Hematology Associates
-
Collierville, Tennessee, United States, 38017
- Family Cancer Center
-
Nashville, Tennessee, United States, 37023
- Tennessee Oncology, PLLC
-
-
Texas
-
Corpus Christi, Texas, United States, 78463
- Coastal Bend Cancer Center
-
-
Virginia
-
Richmond, Virginia, United States, 23235
- Virginia Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed locally advanced or metastatic NSCLC (unresectable stage IIIB or stage IV). Eligible histologies include adenocarcinoma and squamous cell carcinoma. Patients with recurrent disease after treatment for localized NSCLC are also eligible. Cytologic specimens obtained by brushings, washings, or needle aspiration are acceptable.
- At least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques, or as >= 10 mm with spiral computerized tomography (CT) scan according to the Response Evaluation Criteria in Solid Tumors (RECIST).
- Failure of at least one, and no more than two prior cytotoxic chemotherapy regimens for advanced disease (either due to progressive disease or toxicity).
- Recovery from any toxic effects of prior therapy to <= grade 1.
- Completion of radiation therapy at least 28 days prior to the start of study treatment (not including palliative local radiation). Previously irradiated lesions in the advanced setting cannot be included as target lesions unless clear tumor progression has been observed since the end of radiation.
- An ECOG performance status of 0-2.
- Absolute neutrophil count (ANC) >= 1,500, platelets >= 75,000.
- Hemoglobin >= 9 g/dL (within 7 days prior to study treatment).
- International normalized ratio (INR) <= 1.5 or prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution
- Serum creatinine <= 1.5 x institutional upper limit of normal (ULN) within 7 days prior to study treatment.
- Transaminases <= 3 x institutional ULN
- Agreement of female patients of childbearing potential and male patients who have partners of childbearing potential to use an effective form of contraception to prevent pregnancy during treatment, and for a minimum of 90 days thereafter.
- Patients who have treated brain metastases >= 4 weeks out (with surgery and/or radiation therapy) and no evidence of CNS progression.
Exclusion Criteria:
- Past or current history of neoplasm (other than the entry diagnosis), with the exception of treated non-melanoma skin cancer or carcinoma in-situ of the cervix, or other cancers cured by local therapy alone, and a disease-free survival (DFS) >= 3 years.
- Patients who have mixed tumors with small-cell elements are ineligible.
- Pregnancy or lactation.
- Prior treatment with EGFR TKIs or VEGFR TKIs for NSCLC. [NOTE: prior cetuximab and/or bevacizumab use is permitted].
- Significant cardiac disease within 90 days of starting study treatment
- Myocardial infarction within 6 months prior to initiation of study treatment.
- Cardiomegaly on chest imaging or ventricular hypertrophy on electrocardiogram (ECG)
- Poorly controlled hypertension
- Unstable angina (anginal symptoms at rest).
- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
- Presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia.
- A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
- A major surgical procedure, open biopsy, or significant traumatic injury within 28 days of beginning treatment, or anticipation of the need for major surgery during the course of the study.
- Stroke or transient ischemic attack (TIA) within the past 6 months.
- Any prior history of hypertensive crisis or hypertensive encephalopathy.
- Pulmonary hemorrhage/bleeding event >= grade 2 within 28 days of study treatment.
- Any other non-pulmonary hemorrhage/bleeding event >= grade 3 within 28 days of study treatment.
- Evidence or history of bleeding diathesis or coagulopathy.
- Serious non-healing wound, ulcer, or bone fracture.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination Therapy
Erlotinib + Sorafenib
|
Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
Other Names:
|
Placebo Comparator: Placebo
Erlotinib + Placebo
|
Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Objective Response Rate (ORR)
Time Frame: 18 months
|
Overall response rate (ORR) is defined as the percentage of patients who have a partial or complete response to therapy. Responses were assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.0). Complete Response: Disappearance of all target lesions, and disappearance of all non-target lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter of target lesions (taking as reference the baseline sum of longest diameters) |
18 months
|
Progression Free Survival (PFS)
Time Frame: 18 months
|
Progression-free survival is defined as the time from the first day of treatment until the day tumor progression was documented. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST). Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions |
18 months
|
Disease Control Rate (DCR)
Time Frame: 18 months
|
Disease Control Rate (DCR) is defined as the percentage of patients who have a partial/complete/stable response to therapy. Responses were assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.0). Complete Response: Disappearance of all target lesions, and disappearance of all non-target lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter of target lesions (taking as reference the baseline sum of longest diameters) Stable Response: Neither sufficient shrinkage to qualify for partial response, nor sufficient increase to qualify for progressive disease (taking as reference the smallest sum of diameters since the treatment started). |
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response
Time Frame: 18 months
|
Duration of response is defined as the time from when objective response is realized until time to first documented disease progression.
Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Objective Response = CR + PR.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.
|
18 months
|
6-month PFS
Time Frame: 6 months
|
Progression free survival is defined as the time from the first day of treatment until the day tumor progression was documented.
Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST).
Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions (1).
Percentage of participants who were progression free at 6 month from the start of treatment is reported here.
|
6 months
|
Overall Survival (OS)
Time Frame: 18 months
|
OS is defined as the time from the first treatment until date of death due to any cause.
In the absence of confirmation of death or lack of data beyond follow-up period, the survival time was censored to last date the participant was known to be alive.
|
18 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: David Spigel, M.D., SCRI Development Innovations, LLC
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Sorafenib
Other Study ID Numbers
- SCRI LUN 160
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Erlotinib + Sorafenib
-
Free University Medical CenterUnknownNon-Small Cell Lung CancerNetherlands
-
University Health Network, TorontoNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificCanada
-
BayerCompletedCarcinoma, HepatocellularBelgium, France, Spain, Hong Kong, United States, Canada, Germany, Greece, New Zealand, Russian Federation, Australia, Taiwan, Austria, United Kingdom, China, Israel, Korea, Republic of, Bulgaria, Brazil, Poland, Italy, Colombia, South... and more
-
SanofiTerminatedLiver CarcinomaFrance
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
SCRI Development Innovations, LLCBayer; OSI PharmaceuticalsCompletedNon-Small Cell Lung CancerUnited States
-
SCRI Development Innovations, LLCBayerCompletedRefractory Solid TumorsUnited States
-
Medical University of South CarolinaCompletedLiver CancerUnited States
-
National Cancer Institute (NCI)CompletedHilar Cholangiocarcinoma | Recurrent Gallbladder Carcinoma | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Gallbladder Adenocarcinoma | Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Bile Duct Adenocarcinoma | Gallbladder Adenocarcinoma With Squamous... and other conditionsUnited States
-
Yonsei UniversityUnknown